Tetanus Toxoid Vaccine Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Tetanus Toxoid Vaccine Market Analysis
The tetanus toxoid vaccine market is expected to register a CAGR of 4.8% during the forecast period.
The tetanus toxoid vaccine market was significantly impacted by COVID-19 during the initial phases since immunization programs were delayed due to the lockdown, and many countries experienced a shortage of vaccines. As per an article published in May 2022 in the Obstetrics and Gynaecology journal, during the second quarter of the pandemic, when many prenatal visits were done via telemedicine, patients were 1.3 times more likely not to receive Tdap vaccination (54%). Additionally, according to an article published in the Frontier Journal in October 2021, vaccination against diphtheria or tetanus was linked to less severe COVID-19 symptoms. By stimulating the immune system, these vaccinations may protect against severe COVID-19 symptoms. Currently, the market is anticipated to witness growth due to the rise in vaccination and immunization by the government, growth in research and development for tetanus vaccines, and their combination.
Tetanus, also known as lockjaw disease, is a non-communicable serious disease caused by a bacterial toxin that affects the nervous system, leading to painful muscle contractions, particularly the jaw and neck muscles. It is caused by Clostridium tetani (C. tetani) found in human and animal feces, soil, and street dust. Different vaccines include protection against tetanus DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine. For instance, according to the WHO, 9,707 cases of tetanus were reported in 2021 globally. As per the same source, 4,140 cases of neonatal tetanus were reported in 2021.
Furthermore, as per a Global Health Policy January 2022 report, through June 30, 2021, cumulative U.S. contributions made up 13% of all funds received by Gavi, an independent public-private partnership and multilateral funding mechanism that aims to expand global access to the use of vaccines, particularly among vulnerable children (nearly USD 2.8 billion out of more than USD 21 billion). Over time, U.S. donations have increased, recently reaching an annual level of USD 290 million.
Moreover, product launches and collaborations to develop tetanus vaccination and immunization are other driving factors of the tetanus toxoid vaccine market. For instance, in March 2021, Stablepharma collaborated with the European vaccine manufacturer BB-NCIPD (Bul Bio) to develop a thermally stable version of the tetanus-diphtheria (Td) vaccine using the patented StablevaX formulation and device.
On the other hand, the side effects associated with the toxoid vaccine restrain the market growth over the forecast period.
Tetanus Toxoid Vaccine Market Trends
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Segment is Expected to Hold a Significant Market Share in the Tetanus Toxoid Vaccine Market Over the Forecast Period
Diphtheria, tetanus, and pertussis (DTaP) vaccine segment are anticipated to witness growth in the tetanus toxoid vaccine market owing to factors such as growing government initiatives to eradicate these diseases, a rise in product launches and an increase in pipeline studies for the development of DTaP vaccines. DTaP is a vaccine that helps in developing immunity against three deadly diseases, diphtheria, tetanus, and whooping cough (pertussis), in children younger than seven years old. According to a vaccine-preventable disease update by the WHO in 2022, a total number of 144 cases of diphtheria were reported by seven countries (Austria, France, Germany, Italy, Norway, Switzerland, and the United Kingdom), many of which were among asylum seekers. Of the 144 cases, 97 (69%) were classified as clinically compatible, 44 (31%) were laboratory confirmed as toxigenic diphtheria cases, and 3 (2%) were suspected cases.
Moreover, as per a July 2022 update from the WHO, in 2021, about 81% of infants worldwide (105 million infants) received 3 doses of the diphtheria-tetanus-pertussis (DTP3) vaccine, protecting them against infectious diseases that can cause serious illness and disability or be fatal. Furthermore, as per the 2022 Provisional Pertussis Surveillance Report published by CDC, 2,388 cases of pertussis were reported in the United States in 2022, up from 1,609 cases in 2021. Hence, an increase in pertussis cases is likely to demand the availability of vaccines and thereby driving the segment growth.
Additionally, collaborations by key players to launch the DTap vaccines in different countries boost the market growth. For instance, in June 2021, Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus toxoids vaccine) in the United States.
North America is Expected to Hold a Significant Share in the Market during the Forecast Period
North America is expected to hold a significant market share in the tetanus toxoid vaccine market due to the increase in increasing government initiatives programs for vaccination, the surge in diphtheria, pertussis, and tetanus cases, and the rise in research initiatives for the development of vaccines. According to a November 2022 update from the Department of Minnesota, 22 cases of pertussis were reported in the Minnesota region till November 2022. Furthermore, as per the Florida Health Report, in 2022, 47 pertussis cases were reported in 18 counties. There was a 45% increase in the number of pertussis cases reported between May 2022 to October 2022 compared to May 2021 to October 2021 (n=22 cases).
Furthermore, the rise in government initiatives for vaccinations against tetanus and diphtheria boost the market growth over the forecast period. For instance, in April 2022, Ontario expanded its publicly funded Tdap immunization program to include a routine dose in every pregnancy for protection against pertussis, regardless of previous Tdap immunization history. Canada's National Advisory Committee on Immunization recommended that all pregnant individuals get the pertussis (whooping cough) vaccine during every pregnancy to help protect the baby after birth.
Tetanus Toxoid Vaccine Industry Overview
The tetanus toxoid vaccine market is fragmented and competitive in nature. The market consists of several major players. Some of the prominent players that are currently dominating the market are Merck KGaA, GSK PLC, Sanofi (Sanofi Pasteur Inc.), Pfizer Inc., Bharat Biotech, Astellas Pharma Inc., Panacea Biotec Ltd, BB - NCIPD Ltd, PT Bio Farma, and Biological E Limited.
Tetanus Toxoid Vaccine Market Leaders
Sanofi (Sanofi Pasteur, Inc)
Pfizer, Inc
Bharat Biotech
Merck KGaA
GSK plc
*Disclaimer: Major Players sorted in no particular order
Tetanus Toxoid Vaccine Market News
- In August 2022, IBSS Biomed S.A. sponsored a clinical trial to assess the immunogenicity and safety of booster immunization with the bivalent vaccine against tetanus and diphtheria CLODIVAC (IBSS BIOMED S.A.) and Td-Impfstoff Mérieux (Sanofi Pasteur) in healthy adults.
- In August 2022, the Public Health and Family Welfare Minister of Madhya Pradesh, India, launched the state-level program of the DPT/TD vaccination campaign at the Kamala Nehru Girls School Auditorium, Bhopal.
Tetanus Toxoid Vaccine Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Tetanus and Diphtheria in Some Countries
4.2.2 Growing Research and Development Activities for New Vaccines
4.2.3 Increasing Government Initiatives Programs for Vaccination
4.3 Market Restraints
4.3.1 Side-effects Associated with Toxoid Vaccine
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Vaccine Type
5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)
5.1.2 Diphtheria and Tetanus (DT)
5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)
5.1.4 Other Vaccine Types
5.2 By End User
5.2.1 Hospitals and Clinics
5.2.2 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Merck KGaA
6.1.2 GSK Plc
6.1.3 Sanofi (Sanofi Pasteur Inc.)
6.1.4 Pfizer Inc.
6.1.5 Bharat Biotech
6.1.6 Astellas Pharma Inc.
6.1.7 Panacea Biotec Ltd
6.1.8 BB - NCIPD Ltd
6.1.9 PT Bio Farma
6.1.10 Biological E Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Tetanus Toxoid Vaccine Industry Segmentation
As per the scope of the report, the tetanus vaccine, also known as tetanus toxoid, is a toxoid vaccine used to prevent tetanus. During childhood, five doses are recommended, with a sixth given during adolescence. After three doses, almost everyone is initially immune, but additional doses every ten years are recommended to maintain immunity.
The tetanus toxoid vaccine market is segmented by Vaccine Type (Diphtheria, Tetanus, and Pertussis (DTaP), Diphtheria and Tetanus (DT), Tetanus, Diphtheria, and Pertussis (Tdap), Other Vaccines), End User (Hospitals and Clinics, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD) for the above segments.
| By Vaccine Type | |
| Diphtheria, Tetanus, and Pertussis (DTaP) | |
| Diphtheria and Tetanus (DT) | |
| Tetanus, Diphtheria, And Pertussis (Tdap) | |
| Other Vaccine Types |
| By End User | |
| Hospitals and Clinics | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Tetanus Toxoid Vaccine Market Research FAQs
What is the current Global Tetanus Toxoid Vaccine Market size?
The Global Tetanus Toxoid Vaccine Market is projected to register a CAGR of 4.80% during the forecast period (2024-2029)
Who are the key players in Global Tetanus Toxoid Vaccine Market?
Sanofi (Sanofi Pasteur, Inc), Pfizer, Inc, Bharat Biotech, Merck KGaA and GSK plc are the major companies operating in the Global Tetanus Toxoid Vaccine Market.
Which is the fastest growing region in Global Tetanus Toxoid Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Tetanus Toxoid Vaccine Market?
In 2024, the North America accounts for the largest market share in Global Tetanus Toxoid Vaccine Market.
What years does this Global Tetanus Toxoid Vaccine Market cover?
The report covers the Global Tetanus Toxoid Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Tetanus Toxoid Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Tetanus Toxoid Vaccine Industry Report
Statistics for the 2024 Tetanus Toxoid Vaccine market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Tetanus Toxoid Vaccine analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
